Skip to main content
What can we learn from Oral Surveillance? The Oral Surveillance trial has almost become a household word for rheumatologists.
I Need a Nemesis
A nemesis is so much more than the "enemy". Your nemesis defines what matters most to you and how you will overcome. Seth Godin once said, “Pick your enemies, pick your future”.
Review on reactive arthritis & COVID: 22 articles , 25 pts (14M:11F), age 45 yrs. Oligoarthritis was most common. On

Dr. John Cush RheumNow

4 years 3 months ago
Review on reactive arthritis & COVID: 22 articles , 25 pts (14M:11F), age 45 yrs. Oligoarthritis was most common. Onset (COVID to arthritis) was 6-48 days. Steroids in 13, 2 w/ SSZ, Sxs improved 22/25, mean resolution was 16 +/- 57 days https://t.co/0YABcjz9Gk https://t.co/W5Vnn1NjkD
RT @Yuz6Yusof: #LB0004 #EULAR2022 Positive Phase 2 results in #lupus! Deucravacitinib, a TYK2-inhibitor reported signifi

Md Yuzaiful Md Yusof Yuz6Yusof

4 years 3 months ago
#LB0004 #EULAR2022 Positive Phase 2 results in #lupus! Deucravacitinib, a TYK2-inhibitor reported significantly more SRI-4 response rates in DEUC vs PBO. PBO: 34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety. Will proceed to Phase 3 @RheumNow https://t.co/cZLv6bbHer
Canadian study of 50,883 RA pts shows only 58% saw a rheumatologist yearly for 5 yrs. If >65 yrs, Rheum care assoc

Dr. John Cush RheumNow

4 years 3 months ago
Canadian study of 50,883 RA pts shows only 58% saw a rheumatologist yearly for 5 yrs. If >65 yrs, Rheum care assoc w/ DMARD use in 82%; but was only 31% if not under Rheum care. Worse rheum retention with age >81, male, lower SES, older Rheums https://t.co/xUxWaksgsE
Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent rheumatoid arthritis occurring in at-risk individuals. While it is often a point of substantive discussion at EULAR, this year’s meeting in Copenhagen provided further data on how therapy might useful before patients develop rheumatoid arthritis (RA), particularly for those at particularly high risk.
Difficult and complicated oral ulcerations - useful algorithm and expert guideline on diagnosis and approach https://t.

Dr. John Cush RheumNow

4 years 3 months ago
Difficult and complicated oral ulcerations - useful algorithm and expert guideline on diagnosis and approach https://t.co/oksbEpFOAM
FDA approved another rituximab biosimilar, rituximab-arrx (Riabni) (from Amgen), for use w/ MTX in active RA. Riabni is

Dr. John Cush RheumNow

4 years 3 months ago
FDA approved another rituximab biosimilar, rituximab-arrx (Riabni) (from Amgen), for use w/ MTX in active RA. Riabni is not currently approved for B-cell NHL, B-cell leukemia, MPA, or GPA. or pemphigus vulgaris (RTX is an orphan drug) https://t.co/Htk0xBx63X https://t.co/ep1L3YO9hl
Despite updated gout management guidelines from European (EULAR) and British (BSR) societies, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.
×